Cancer Immunology, Immunotherapy

, Volume 55, Issue 10, pp 1185–1197 | Cite as

Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites

  • Helena Harlin
  • Todd V. Kuna
  • Amy C. Peterson
  • Yuru Meng
  • Thomas F. GajewskiEmail author
Original Article


Although melanoma tumors usually express antigens that can be recognized by T cells, immune-mediated tumor rejection is rare. In many cases this is despite the presence of high frequencies of circulating tumor antigen-specific T cells, suggesting that tumor resistance downstream from T cell priming represents a critical barrier. Analyzing T cells directly from the melanoma tumor microenvironment, as well as the nature of the microenvironment itself, is central for understanding the key downstream mechanisms of tumor escape. In the current report we have studied tumor-associated lymphocytes from a patient with metastatic melanoma and large volume malignant ascites. The ascites fluid showed abundant tumor cells that expressed common melanoma antigens and retained expression of class I MHC and antigen processing machinery. The ascites fluid contained the chemokines CCL10, CCL15, and CCL18 which was associated with a large influx of activated T cells, including CD8+ T cells recognizing HLA-A2 tetramer complexes with peptides from Melan-A and NA17-A. However, several functional defects of these tumor antigen-specific T cells were seen, including poor production of IFN-γ in response to peptide-pulsed APC or autologous tumor cells, and lack of expression of perforin. Although these defects were T cell intrinsic, we also observed abundant CD4+CD25+FoxP3+ T cells, as well as transcripts for FoxP3, IL-10, PD-L1/B7-H1, and indoleamine-2,3-dioxygenase (IDO). Our observations suggest that, despite recruitment of large numbers of activated CD8+ T cells into the tumor microenvironment, T cell hyporesponsiveness and additional negative regulatory mechanisms can limit the effector phase of the anti-tumor immune response.


Cytotoxic T cells Tumor immunity Tolerance Cell differentiation 



The authors thank Alpana Sahu for technical assistance. This work was supported in part by NIH R01 CA90575, a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, and the Ludwig Institute for Cancer Research.


  1. 1.
    Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380CrossRefPubMedGoogle Scholar
  2. 2.
    Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S (2003) Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 24:335CrossRefPubMedGoogle Scholar
  3. 3.
    Delp K, Momburg F, Hilmes C, Huber C, Seliger B (2000) Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin. Bone Marrow Transplant 25(Suppl 2):S88CrossRefPubMedGoogle Scholar
  4. 4.
    Peterson AC, Harlin H, Gajewski TF (2003) Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21:2342CrossRefPubMedGoogle Scholar
  5. 5.
    Plebanski M, Allsopp CE, Aidoo M, Reyburn H, Hill AV (1995) Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. Eur J Immunol 25:1783PubMedCrossRefGoogle Scholar
  6. 6.
    Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, Cerundolo V, McMichael AJ, Rowland-Jones SL (2002) Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8:379CrossRefPubMedGoogle Scholar
  7. 7.
    Clay TM, Custer MC, McKee MD, Parkhurst M, Robbins PF, Kerstann K, Wunderlich J, Rosenberg SA, Nishimura MI (1999) Changes in the fine specificity of gp100(209–217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J Immunol 162:1749PubMedGoogle Scholar
  8. 8.
    Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M, Weber JS, Lee PP (2004) Diversity and recognition efficiency of T cell responses to cancer. PLoS Med 1:e28CrossRefPubMedGoogle Scholar
  9. 9.
    Yang S, Linette GP, Longerich S, Haluska FG (2002) Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J Immunol 169:531PubMedGoogle Scholar
  10. 10.
    Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756PubMedGoogle Scholar
  11. 11.
    Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766PubMedGoogle Scholar
  12. 12.
    Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211PubMedGoogle Scholar
  13. 13.
    Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942CrossRefPubMedGoogle Scholar
  14. 14.
    Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ (2002) Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 101:151CrossRefPubMedGoogle Scholar
  15. 15.
    Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269CrossRefPubMedGoogle Scholar
  16. 16.
    Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor EM, Antonia S, Ochoa JB, Ochoa AC (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64:5839CrossRefPubMedGoogle Scholar
  17. 17.
    He YF, Zhang GM, Wang XH, Zhang H, Yuan Y, Li D, Feng ZH (2004) Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol 173:4919PubMedGoogle Scholar
  18. 18.
    Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF (2004) PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 64:1140CrossRefPubMedGoogle Scholar
  19. 19.
    Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293CrossRefPubMedGoogle Scholar
  20. 20.
    Ferrone S, Marincola FM (1995) Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487CrossRefPubMedGoogle Scholar
  21. 21.
    Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, Oesch F, Knuth A (1997) Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 71:142CrossRefPubMedGoogle Scholar
  22. 22.
    Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, Rimoldi D, Guillaume P, Meidenbauer N, Mackensen A, Rufer N, Lubenow N, Speiser D, Cerottini JC, Romero P, Pittet MJ (2004) Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 64:2865CrossRefPubMedGoogle Scholar
  23. 23.
    Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, Hemmi S, Hengartner H, Zinkernagel RM (2001) Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411:1058CrossRefPubMedGoogle Scholar
  24. 24.
    Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, D’Ambrosio D (2001) Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 194:847CrossRefPubMedGoogle Scholar
  25. 25.
    Rosenberg SA, Dudley ME (2004) Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 101(Suppl 2):14639CrossRefPubMedGoogle Scholar
  26. 26.
    Labarriere N, Pandolfino MC, Raingeard D, Le Guiner S, Diez E, Le Drean E, Dreno B, Jotereau F (1998) Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes. Int J Cancer 78:209CrossRefPubMedGoogle Scholar
  27. 27.
    Labarriere N, Diez E, Pandolfino MC, Viret C, Guilloux Y, Le Guiner S, Fonteneau JF, Dreno B, Jotereau F (1997) Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J Immunol 158:1238PubMedGoogle Scholar
  28. 28.
    Gervois N, Guilloux Y, Diez E, Jotereau F (1996) Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J Exp Med 183:2403CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Helena Harlin
    • 1
  • Todd V. Kuna
    • 1
  • Amy C. Peterson
    • 1
  • Yuru Meng
    • 2
  • Thomas F. Gajewski
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of Medicine, Section of Hematology/OncologyUniversity of ChicagoChicagoUSA
  2. 2.Department of PathologyUniversity of ChicagoChicagoUSA
  3. 3.Committees on Immunology and Cancer BiologyUniversity of ChicagoChicagoUSA

Personalised recommendations